CBO report highlights rising cost of brand-name drugs in Medicare as Congress considers price negotiations
As the Democrats’ big shot at major drug pricing reform hangs in the balance, the Congressional Budget Office has released a new report showing the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
